Table 5.
CTRCD at the End of Anthracycline Therapy and at Extended Follow-Up
| CTRCD at the End of Anthracyclines (n = 115) |
CTRCD at Extended Follow-Up (n = 103) |
|
|---|---|---|
| No | Yes | |
| Sex-specific cTnT | ||
| No | 45 (44) | 5 (5) |
| Yes | 46 (45) | 6 (6) |
| Sex-specific cTnI | ||
| No | 86 (84) | 4 (4) |
| Yes | 12 (12) | 0 (0) |
| Sex-neutral cTnT | ||
| No | 74 (73) | 4 (4) |
| Yes | 24 (24) | 0 (0) |
| Sex-neutral cTnI | ||
| No | 91 (89) | 4 (4) |
| Yes | 7 (7) | 0 (0) |
Values are n (%). The table is to be interpreted as follows: 115 and 103 participants were assessed for CTRCD at the end of anthracycline therapy and at extended follow-up, respectively, and 102 participants were assessed at both time points. When assessed using the sex-specific cTnT upper reference limit as a cutoff, 44% did not have CTRCD at either time point, 45% had CTRCD the end of anthracycline therapy but not at extended follow-up, 5% had CTRCD at extended follow-up only, and 6% had CTRCD at both time points.
Abbreviations as in Table 3.